|
시장보고서
상품코드
2078014
폐 약물전달 시스템 시장 : 제품 유형별, 용도별, 유통 채널별, 지역별Pulmonary Drug Delivery Systems Market, By Product type, By Application, By Distribution Channel, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) |
||||||
폐 약물전달 시스템 시장은 2026년에 393억 7,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 546억 7,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.8%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 393억 7,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 4.80% | 2033년 시장 규모 예측: | 546억 7,000만 달러 |
폐 경로를 통한 약물전달은 환자가 흡입기를 사용하여 약물을 흡입하고, 폐 점막을 통해 혈액으로 흡수되는 투여 경로입니다. 호흡기질환의 치료에 있어, 질환 부위에 직접 작용하는 한편, 약물의 전신 흡수를 위해 넓은 표면적과 효소 작용이 비교적 적고 통제된 환경을 제공합니다.
폐 경로를 통한 약물전달은 전신성 질환 치료 시 투여 경로로서, 정맥내 투여, 경구 투여, 구강 점막 투여, 경피 투여, 질 내 투여, 비강내 투여 또는 안구 내 투여와 비교할 때 몇 가지 장점이 있습니다.
시장 역학
주요 시장 참여자들은 제품 포트폴리오 확대를 위한 규제 당국의 제품 승인 등 유기적 성장 전략에 주력하고 있으며, 이는 예측 기간 동안 전 세계 폐 약물전달 시스템 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2020년 7월, 제약회사 노바티스 AG는 유럽위원회(EC)가 'Enerzair Breezhaler'를 성인 환자의 천식 유지 요법으로 승인했다고 발표했습니다. 이 승인에는 흡입 확인, 복약 알림, 그리고 치료 관련 의사결정을 보다 적절하게 지원하기 위한 객관적인 데이터에 대한 접근을 제공하는 센서와 앱이 탑재된 선택적 디지털 동반자 기능도 포함되어 있습니다.
주요 시장 참여자들의 호흡기질환 치료를 위한 연구 개발 활동이 활발해짐에 따라, 예측 기간 동안 시장 성장을 견인할 것으로 전망됩니다. 예를 들어, 2020년 12월, 인타스 파마슈티컬스는 천식 및 만성 폐쇄성 폐질환(COPD)을 포함한 호흡기질환 치료에 근본적인 이점을 제공하는 첨단 흡입 제제의 개발에 주력하고 있으며, 이 개발 과정에 구강내 분해 정제 기술이 활용되고 있다고 발표했습니다. 이 약물전달 시스템은 제제의 신속한 분해를 가능하게 하도록 설계되어, 약효 발현을 빠르게 하고 있습니다. 이 기술은 호흡기질환을 앓고 있는 소아, 노인 및 정신과 환자를 대상으로, 투여의 용이성 제고, 환자의 복약 순응도 향상 및 투여 편의성 증진을 위해 여러 분자에 적용되고 있습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 폐 약물전달 시스템 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- '세계 폐 약물전달 시스템 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 폐 약물전달 시스템 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 폐 약물전달 시스템 시장 : 제품 유형별, 2021-2033년
제5장 세계의 폐 약물전달 시스템 시장 : 용도별, 2021-2033년
제6장 세계의 폐 약물전달 시스템 시장 : 유통 채널별, 2021-2033년
제7장 세계의 폐 약물전달 시스템 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.07.09Pulmonary Drug Delivery Systems Market is estimated to be valued at USD 39.37 Bn in 2026 and is expected to reach USD 54.67 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 39.37 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.80% | 2033 Value Projection: | USD 54.67 Bn |
Pulmonary drug delivery is a route of administration in which patients use an inhaler to inhale its medications, and drugs are absorbed into the bloodstream via the lung mucous membrane. It provides direct access to disease in the treatment of respiratory diseases, while providing an enormous surface area and a relatively low enzymatic, controlled environment for systemic absorption of medications.
Pulmonary drug delivery offers several advantages as a route of administration for the treatment of systemic diseases compared with intravenous, oral, buccal, transdermal, vaginal, nasal or ocular administration.
Market Dynamics
The key market players are focused on organic growth strategies such as product approval by regulatory authorities to expand its product portfolio is expected to drive the global pulmonary drug delivery systems market growth over the forecast period. For instance, in July 2020, Novartis AG, a pharmaceutical company, announced that the European Commission (EC) has approved Enerzair Breezhaler, as a maintenance treatment of asthma in adult patients. The approval also includes an optional digital companion with sensor and app that provides inhalation confirmation, medication reminders and access to objective data to better support therapeutic decisions.
The increasing research and development activities by key market players for the treatment of pulmonary diseases is expected to drive the market growth over the forecast period. For instance, in December 2020, Intas Pharmaceuticals Ltd., announced that the company was focused on developing advanced inhalation formulation having fundamental advantages in the therapy of diseases of the respiratory tract, including asthma and Chronic Obstructive Pulmonary Disease with Orally Disintegrating Tablet Technology. The Drug delivery system designed for rapid disintegration of the product ensuring faster onset of action. This technology is used for several molecules to facilitate ease of administration and improved patient compliance & convenient dosing for paediatric, geriatric, and psychiatric patients with respiratory diseases.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global pulmonary drug delivery systems marketbased on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca, Boehringer Ingelheim International GmbH., CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Koninklijke Philips N.V.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary drug delivery systems market
Detailed Segmentation:
- Global Pulmonary Drug Delivery Systems Market, By Product Type (Revenue, USD Bn, 2021 - 2033):
- Nebulizers
- Dry Powder Inhalers (DPIs)
- Metered Dose Inhalers (MDIs)
- Global Pulmonary Drug Delivery Systems Market, By Application (Revenue, USD Bn, 2021 - 2033):
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Global Pulmonary Drug Delivery Systems Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033):
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Pulmonary Drug Delivery Systems Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- 3M Health Care
- Allied Healthcare Products, Inc.
- straZeneca
- Boehringer Ingelheim International GmbH.
- CareFusion Corporation
- GF Health Products, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
- Koninklijke Philips N.V.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
4. Global Pulmonary Drug Delivery Systems Market, By Product Type, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Nebulizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Dry Powder Inhalers (DPIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Metered Dose Inhalers (MDIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Segment Trends
5. Global Pulmonary Drug Delivery Systems Market, By Application, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Cystic Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Allergic Rhinitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
6. Global Pulmonary Drug Delivery Systems Market, By Distribution Channel, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
7. Global Pulmonary Drug Delivery Systems Market, By Region, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Modality, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- 3M Health Care
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Allied Healthcare Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CareFusion Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GF Health Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Omron Healthcare, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PARI Respiratory Equipment, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Koninklijke Philips N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
